When we discuss the life sciences, perhaps it isn’t always apparent just how many sectors “life sciences” can cover. From drug discovery and development to stratified medicine, med-tech to stem cells and regenerative medicine, the life science industry is thriving here in Scotland and MBM is pleased to represent clients from across the sector.
A recent success story for one of our clients has been the £3.1 million investment in the synthetic bone graft company Sirakoss by a syndicate of investors led by Epidarex Capital. The presence of this dedicated life science venture capital fund in the under ventured Scottish market continues to provide optimism that innovative Scottish companies can attract substantial investment.
Providing an “ecosystem” for life science companies to grow is provided ably by bio-incubators Edinburgh BioQuarter and BioCity Scotland. MBM has continued to support both incubators in 2014 through social media and participating in events. We are particularly delighted to now be a corporate partner of BioCity Scotland, with Dr. Julie Nixon regularly on site at the Newhouse complex. As part of an £18million funding package for life sciences announced by George Osborne in July, BioCity Scotland is to establish “MediCity Scotland” at Newhouse. With med-tech surpassing pharma as an employer in the UK, MediCity Scotland will enable the creation of over 50 new healthcare businesses in Scotland over the next 5 years creating over 350 jobs as a result. MBM looks forward to being part of this exciting venture.